Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVBPNASDAQ:CRONNASDAQ:ESPRNASDAQ:REPL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$19.80-4.8%$19.69$15.47▼$36.37$674.23M1.47173,175 shs182,006 shsCRONCronos Group$1.85-2.6%$1.83$1.60▼$3.14$713.00M1.061.34 million shs1.46 million shsESPREsperion Therapeutics$0.98-7.1%$1.30$0.82▼$3.94$193.29M0.755.66 million shs4.75 million shsREPLReplimune Group$7.50-25.1%$9.75$4.92▼$17.00$577.61M0.68886,140 shs4.05 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma-2.30%-0.53%+26.74%-26.18%+20.78%CRONCronos Group+3.26%+3.83%+11.11%+1.06%-29.10%ESPREsperion Therapeutics-3.67%+15.73%-14.63%-44.15%-49.52%REPLReplimune Group0.00%+7.98%+34.18%-28.55%+44.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVBPArriVent BioPharma1.1618 of 5 stars3.60.00.00.02.80.00.0CRONCronos Group1.5518 of 5 stars2.04.00.00.02.90.01.3ESPREsperion Therapeutics3.3884 of 5 stars3.31.00.03.92.01.70.6REPLReplimune Group4.0575 of 5 stars3.62.00.04.53.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVBPArriVent BioPharma 3.17Buy$39.0096.93% UpsideCRONCronos Group 0.00N/A$3.5089.19% UpsideESPREsperion Therapeutics 2.50Moderate Buy$6.42557.78% UpsideREPLReplimune Group 3.13Buy$19.43159.05% UpsideCurrent Analyst Ratings BreakdownLatest ESPR, REPL, AVBP, and CRON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/25/2025ESPREsperion TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/25/2025ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/17/2025ESPREsperion TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$4.00 ➝ $3.004/8/2025ESPREsperion TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/20/2025AVBPArriVent BioPharmaB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$37.003/20/2025ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.003/19/2025AVBPArriVent BioPharmaB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/10/2025AVBPArriVent BioPharmaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$45.003/7/2025AVBPArriVent BioPharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$39.00 ➝ $39.003/4/2025ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.002/26/2025REPLReplimune GroupJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$16.00 ➝ $18.00(Data available from 5/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVBPArriVent BioPharmaN/AN/AN/AN/A($4.79) per shareN/ACRONCronos Group$117.62M6.06N/AN/A$2.87 per share0.64ESPREsperion Therapeutics$332.31M0.58N/AN/A($3.85) per share-0.25REPLReplimune GroupN/AN/AN/AN/A$6.26 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVBPArriVent BioPharma-$69.33M-$2.57N/AN/AN/AN/A-43.89%-29.67%5/14/2025 (Estimated)CRONCronos Group-$73.96M$0.10N/A61.671.74-42.65%-2.56%-2.47%5/8/2025 (Estimated)ESPREsperion Therapeutics-$209.25M-$0.25N/AN/AN/A-29.37%N/A-10.77%5/6/2025 (Estimated)REPLReplimune Group-$215.79M-$3.07N/AN/AN/AN/A-54.84%-42.97%5/15/2025 (Estimated)Latest ESPR, REPL, AVBP, and CRON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q4 2025REPLReplimune Group-$0.75N/AN/AN/AN/AN/A5/14/2025Q1 2025AVBPArriVent BioPharma-$0.66N/AN/AN/AN/AN/A5/6/2025Q1 2025ESPREsperion Therapeutics-$0.18-$0.21-$0.03-$0.21$54.97 millionN/A3/3/2025Q4 2024AVBPArriVent BioPharma-$0.78-$0.60+$0.18-$0.61N/AN/A2/12/2025Q3 2025REPLReplimune Group-$0.70-$0.79-$0.09-$0.79N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVBPArriVent BioPharmaN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVBPArriVent BioPharmaN/A19.2819.28CRONCronos GroupN/A24.2423.05ESPREsperion TherapeuticsN/A1.851.37REPLReplimune Group0.1411.4311.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVBPArriVent BioPharma9.48%CRONCronos Group8.71%ESPREsperion Therapeutics47.39%REPLReplimune Group92.53%Insider OwnershipCompanyInsider OwnershipAVBPArriVent BioPharmaN/ACRONCronos Group6.90%ESPREsperion Therapeutics1.00%REPLReplimune Group8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVBPArriVent BioPharma4034.05 millionN/AN/ACRONCronos Group450385.41 million356.14 millionOptionableESPREsperion Therapeutics200198.15 million195.07 millionOptionableREPLReplimune Group21077.02 million70.24 millionOptionableESPR, REPL, AVBP, and CRON HeadlinesRecent News About These CompaniesBoxer Capital Management LLC Buys Shares of 1,796,341 Replimune Group, Inc. (NASDAQ:REPL)May 4 at 6:25 AM | marketbeat.comInvesco Ltd. Sells 92,952 Shares of Replimune Group, Inc. (NASDAQ:REPL)May 4 at 3:25 AM | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Shares Purchased by Wells Fargo & Company MNMay 2, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Purchases 1,083,633 Shares of Replimune Group, Inc. (NASDAQ:REPL)April 29, 2025 | marketbeat.comReplimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For MelanomaApril 28, 2025 | seekingalpha.comRenaissance Technologies LLC Buys 49,200 Shares of Replimune Group, Inc. (NASDAQ:REPL)April 28, 2025 | marketbeat.comReplimune Group (NASDAQ:REPL) Trading Down 2.9% - Should You Sell?April 24, 2025 | marketbeat.comDiadema Partners LP Purchases Shares of 114,000 Replimune Group, Inc. (NASDAQ:REPL)April 24, 2025 | marketbeat.comMarshall Wace LLP Takes $10.85 Million Position in Replimune Group, Inc. (NASDAQ:REPL)April 24, 2025 | marketbeat.comJump Financial LLC Has $865,000 Position in Replimune Group, Inc. (NASDAQ:REPL)April 24, 2025 | marketbeat.comReplimune Group (NASDAQ:REPL) Stock Price Up 6.7% - Time to Buy?April 23, 2025 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Position Boosted by Nan Fung Group Holdings LtdApril 21, 2025 | marketbeat.comJPMorgan Chase & Co. Has $5.89 Million Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL)April 20, 2025 | marketbeat.comReplimune Group (NASDAQ:REPL) Trading 4.4% Higher - Here's WhyApril 17, 2025 | marketbeat.comAlliancebernstein L.P. Sells 48,397 Shares of Replimune Group, Inc. (NASDAQ:REPL)April 15, 2025 | marketbeat.comVanguard Group Inc. Has $43.55 Million Holdings in Replimune Group, Inc. (NASDAQ:REPL)April 14, 2025 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of "Buy" from AnalystsApril 13, 2025 | marketbeat.comWellington Management Group LLP Raises Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL)April 12, 2025 | marketbeat.comReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 11, 2025 | globenewswire.comReplimune Group (NASDAQ:REPL) Shares Down 7.1% - Time to Sell?April 11, 2025 | marketbeat.comWhy Replimune Group, Inc.’s (REPL) Stock Is Down 9.10%April 10, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeatDelta, Walmart Cut Profit Targets: Could Start Domino EffectBy Thomas Hughes | April 10, 2025View Delta, Walmart Cut Profit Targets: Could Start Domino EffectESPR, REPL, AVBP, and CRON Company DescriptionsArriVent BioPharma NASDAQ:AVBP$19.80 -1.01 (-4.83%) Closing price 03:59 PM EasternExtended Trading$19.72 -0.09 (-0.45%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.Cronos Group NASDAQ:CRON$1.85 -0.05 (-2.63%) Closing price 04:00 PM EasternExtended Trading$1.84 -0.01 (-0.27%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Esperion Therapeutics NASDAQ:ESPR$0.98 -0.07 (-7.10%) Closing price 04:00 PM EasternExtended Trading$0.98 +0.01 (+0.77%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Replimune Group NASDAQ:REPL$7.50 -2.51 (-25.07%) Closing price 04:00 PM EasternExtended Trading$7.93 +0.43 (+5.68%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Top-Ranked Insider Buys From April by Market Cap Palantir Stock Drops Despite Stellar Earnings: What's Next? Hims & Hers Stock Rises on Fundamentals and Squeeze Potential Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership? D-Wave Quantum: Hidden Opportunity or Short Seller's Dream? Microsoft Stock After Xbox Price Hike: Buy or Hold? Uncertainty Creates Opportunity for Tyson Foods Investors Why Wells Fargo Is Buying $40 Billion of Its Own Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
